[go: up one dir, main page]

DE60136334D1 - Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff - Google Patents

Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff

Info

Publication number
DE60136334D1
DE60136334D1 DE60136334T DE60136334T DE60136334D1 DE 60136334 D1 DE60136334 D1 DE 60136334D1 DE 60136334 T DE60136334 T DE 60136334T DE 60136334 T DE60136334 T DE 60136334T DE 60136334 D1 DE60136334 D1 DE 60136334D1
Authority
DE
Germany
Prior art keywords
respiratorisches
syncytialvirus
impfstoff
für
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60136334T
Other languages
English (en)
Inventor
Ralph A Tripp
Larry J Anderson
Michael P Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE60136334D1 publication Critical patent/DE60136334D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60136334T 2000-02-02 2001-02-02 Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff Expired - Lifetime DE60136334D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17990500P 2000-02-02 2000-02-02
PCT/US2001/003584 WO2001056602A2 (en) 2000-02-02 2001-02-02 Cd40 ligand adjuvant for respiratory syncytial virus

Publications (1)

Publication Number Publication Date
DE60136334D1 true DE60136334D1 (en) 2008-12-11

Family

ID=22658453

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60136334T Expired - Lifetime DE60136334D1 (en) 2000-02-02 2001-02-02 Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff

Country Status (7)

Country Link
US (2) US7371392B2 (de)
EP (1) EP1255560B1 (de)
AT (1) ATE412427T1 (de)
AU (1) AU3480001A (de)
CA (1) CA2399790C (de)
DE (1) DE60136334D1 (de)
WO (1) WO2001056602A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399790C (en) * 2000-02-02 2012-10-30 Ralph A. Tripp Cd40 ligand adjuvant for respiratory syncytial virus
WO2004009789A2 (en) * 2002-07-22 2004-01-29 Vectorlogics, Inc. Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof
US7029756B2 (en) * 2002-11-06 2006-04-18 Kimberly-Clark Worldwide, Inc. Soft tissue hydrophilic tissue products containing polysiloxane and having unique absorbent properties
US8299229B2 (en) 2003-11-24 2012-10-30 Microvax, Llc Mucin antigen vaccine
WO2005058950A2 (en) * 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
US7098495B2 (en) 2004-07-26 2006-08-29 Freescale Semiconducor, Inc. Magnetic tunnel junction element structures and methods for fabricating the same
JP2009514536A (ja) 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター Ｃｄ４０リガンド融合蛋白質ワクチン
EP2066339B1 (de) 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Zusammensetzungen und verfahren zur verstärkung von immunreaktionen
KR100938105B1 (ko) * 2007-09-21 2010-01-21 이화여자대학교 산학협력단 호흡기 신시치아 바이러스 백신
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
ES2622228T3 (es) 2009-03-10 2017-07-06 Baylor Research Institute Vacunas antivíricas dirigidas a células presentadoras de antígenos
CA2754862C (en) 2009-03-10 2019-04-02 Baylor Research Institute Anti-cd40 antibodies and uses thereof
BRPI1009194A2 (pt) 2009-03-10 2016-11-01 Baylor Res Inst vacinas direcionadas à célula apresentadora de antígeno
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
ES2753142T3 (es) 2010-06-09 2020-04-07 Univ Arkansas Vacuna y métodos para reducir una infección por Campylobacter
WO2012135132A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
EP3578190A1 (de) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Zusammensetzungen und verfahren zur verstärkung der immunreaktionen gegen enterale pathogene
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
KR20170129804A (ko) * 2015-03-20 2017-11-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cd40 리간드를 어쥬번트로서 갖는 백신
TWI843057B (zh) 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
JP7640466B2 (ja) * 2019-03-27 2025-03-05 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル Ｃｄ４０活性化特性を有する組換えタンパク質

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
DK0812206T3 (da) 1995-03-01 2002-09-09 Immunex Corp Fremgangsmåde til stimulering af en immunrespons
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6020182A (en) 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
WO1998002180A1 (en) * 1996-07-12 1998-01-22 Connaught Laboratories Limited Two-step immunization procedure against the pyramyxoviridae family of viruses using attenuated viral strains and subunit protein preparation
CA2792479A1 (en) 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
CA2399790C (en) * 2000-02-02 2012-10-30 Ralph A. Tripp Cd40 ligand adjuvant for respiratory syncytial virus

Also Published As

Publication number Publication date
WO2001056602A2 (en) 2001-08-09
EP1255560A2 (de) 2002-11-13
WO2001056602A3 (en) 2002-02-21
ATE412427T1 (de) 2008-11-15
CA2399790A1 (en) 2001-08-09
US8354115B2 (en) 2013-01-15
US20080181915A1 (en) 2008-07-31
CA2399790C (en) 2012-10-30
US7371392B2 (en) 2008-05-13
US20030021808A1 (en) 2003-01-30
EP1255560B1 (de) 2008-10-29
AU3480001A (en) 2001-08-14

Similar Documents

Publication Publication Date Title
DE60136334D1 (en) Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
MXPA05005051A (es) Vacuna de vector adenoviral.
MXPA03000786A (es) Peptidos de promiostatina y metodos de usar los mismos.
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
HK1059267A1 (en) Efficient recovery of correctly refolded proteins
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
AU2002355677A1 (en) Antigenic polypeptides
HK1096427A1 (en) Novel fungal proteins and nucleic acids encoding same
SI2345671T1 (sl) Optimizirane Fc-variante in postopki za njihovo izdelavo
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
SG166117A1 (en) Methods and compositions for treatment of interferon-resistant tumors
DE60118359D1 (de) Humanische pellino-polypeptide
PT1733736E (pt) Método de produção de anticorpos recombinantes contra tumores
WO2003062374A3 (en) Synthetic genes for malarial proteins and methods of use
HK1080712A1 (en) Ihnv g protein for immune stimulation
FR2838742B1 (fr) Epitopes t de l'antigene epha2
EP0972054A4 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
WO2004022092A3 (en) Flagellin peptides as adjuvants for vaccines
MXPA05011716A (es) Gen, polipeptidos y metodos de uso en ghrh canino.
WO2003051305A3 (en) Innate immune system-directed vaccines
WO2002060390A3 (en) Induction of immune responses to isoaspartyl-modified antigens
AU2003240790A1 (en) Antibody peg positional isomers, compositions comprising same, and use thereof
WO2004053052A3 (en) HUMAN RECOMBINANT ENDOOLIGOPEPTIDASE A (hEOPA)
TWI316091B (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition